Stem Cells http://www.epitomics.com
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buchner, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buchner, T.

Stem Cells, Vol 12, 241-252, Copyright © 1994 by AlphaMed Press

REVIEWS

Hematopoietic growth factors in cancer treatment

T Buchner
Department of Internal Medicine/Hematology/Oncology, University of Munster, Germany.

The introduction of hematopoietic growth factors during the past five years has changed the scenery of antitumor treatment. Growth factors following high-dose chemotherapy or bone marrow transplantation have become established as part of many treatment protocols. The main benefits are earlier recovery of neutrophils resulting in fewer days with fever, antibiotics and hospitalization. Growth factors were found to reduce the treatment-related morbidity and to improve the practicability of therapeutic regimens. First studies on a prospective chemotherapy dose intensification supported by growth factors are underway. As a further effect of growth factors, an attempted enhancement of antitumor cytotoxicity by recruitment of tumor cells to chemosensitivity or by modulation of antitumor drug metabolism appears realistic based on first data on growth factor priming in AML. New ways to support high-intensity and myeloablative antitumor strategies are opened by the autologous transplantation of peripheral blood progenitor cells mobilized by growth factors and also by the use of new factors like SCF and the synergistic combination of growth factors as part of future strategies against malignant disorders.


This article has been cited by other articles:


Home page
 BloodHome page
L. A. Ehrlich, H. Y. Chung, I. Ghobrial, S. J. Choi, F. Morandi, S. Colla, V. Rizzoli, G. D. Roodman, and N. Giuliani
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
Blood, August 15, 2005; 106(4): 1407 - 1414.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
S. Gaudron, C. Grillon, J. Thierry, A. Riches, P. K. Wierenga, and J. Wdzieczak-Bakala
In Vitro Effect of Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) Analogs Resistant to Angiotensin I-Converting Enzyme on Hematopoietic Stem Cell and Progenitor Cell Proliferation
Stem Cells, March 1, 1999; 17(2): 100 - 106.
[Abstract] [Full Text]

Home page
 BloodHome page
N. Mach, C. S. Lantz, S. J. Galli, G. Reznikoff, M. Mihm, C. Small, R. Granstein, S. Beissert, M. Sadelain, R. C. Mulligan, et al.
Involvement of Interleukin-3 in Delayed-Type Hypersensitivity
Blood, February 1, 1998; 91(3): 778 - 783.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
Email Content Delivery
Copyright © 1994 by AlphaMed Press.